Skip to main content

Table 4 Group statistics

From: Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia?

Statin use

APOE4

N

Mean

Standard deviation

Standard error of the mean

0

      
 

Age at death

1.00

99

78.96

8.415

0.846

0.00

1459

81.16

10.957

0.287

Education level

1.00

99

15.59

2.966

0.298

0.00

1459

15.72

8.601

0.225

Estimated onset age

1.00

99

111.61

185.605

18.654

0.00

1459

91.61

128.096

3.354

Tauopathy

1.00

99

2.01

0.267

0.027

0.00

1459

.34

2.698

0.071

Density of neocortical neuritic plaques (amyloid CERAD score)

1.00

99

2.60

0.699

0.070

0.00

1459

2.32

0.983

0.026

Braak stage

1.00

99

5.29

1.042

0.105

0.00

1459

4.87

1.488

0.039

1

      
 

Age at death

1.00

16

76.19

6.036

1.509

0.00

242

80.60

8.591

0.552

Education level

1.00

16

14.13

3.074

0.769

0.00

242

15.72

8.290

0.533

Estimated onset age

1.00

16

67.19

4.764

1.191

0.00

242

80.19

84.564

5.436

Tauopathy

1.00

16

2.06

0.250

0.063

0.00

242

0.37

2.673

0.172

Density of neocortical neuritic plaques (amyloid CERAD score)

1.00

16

2.56

0.727

0.182

0.00

242

2.36

0.950

0.061

Braak stage

1.00

16

5.25

0.856

0.214

0.00

242

4.75

1.419

0.091

  1. APO apolipoprotein, CERAD Consortium to Establish a Registry for Alzheimer's Disease
  2. 0 means ApoE 4 NON carrier
  3. 1 means ApoE 4 Carrier